Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Scancell Holdings (SCP0) Stock Price & Analysis

SCP0 Stock Chart & Stats

€1.02-€0.01(-0.78%)
At close: 5:30 PM GMT+1
EUR 0.75EUR 1EUR 1.253 Aug19 Aug25 Aug10 Sep28 Sep16 Oct27 Oct
Day’s Range
EUR 1.02 - EUR 1.03
52-Week Range
EUR 0.72 - EUR 2.90
Previous Close
EUR 1.02
Volume
N/A
Average Volume (3M)
136
Market Cap
EUR 126.67M
Enterprise Value
EUR 209.19M
Total Cash (Recent Filing)
EUR 5.32M
Total Debt (Recent Filing)
EUR 17.08M
Price to Earnings (P/E)
―
Beta
-2.00
Next Earnings
Feb 04, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Clinical And Regulatory Progress

FDA clearance of the registrational Phase III design materially reduces regulatory uncertainty and establishes a defined development route. Acceptance of a surrogate endpoint could shorten the path to approval if efficacy is confirmed, strengthening the commercial potential of iSCIB1+.

Promising Clinical Efficacy Signal

The reported Phase II efficacy signal provides a credible basis for advancing iSCIB1+ into a large confirmatory trial and may support differentiation in melanoma treatment. If replicated prospectively, the result could improve partnering prospects and long-term product value.

Pipeline And Platform Depth

Multiple clinical, preclinical and partnered programs diversify the company beyond a single asset and create several possible development or milestone paths. Long patent protection, scalable manufacturing and the Genmab relationship can support durable value creation if programs advance.

Bears Say

Persistent Losses And Cash Burn

Persistent operating and free cash outflows show that the business is not yet self-funding and must rely on external capital or partner receipts. Continued burn can constrain development choices and make execution more sensitive to financing availability over the next several quarters.

Weak Balance Sheet

Negative equity combined with meaningful debt and a sharply smaller asset base indicates limited financial flexibility. This weak balance sheet increases dependence on new funding, reduces resilience while Phase III spending rises, and may weaken negotiating leverage with prospective partners.

Funding And Development Timing Risk

The funding runway ends well before the expected Phase III readout, creating a structural need for partnering, milestone receipts or additional financing. A prolonged blinded trial also delays definitive validation, increasing dilution and execution risk before commercial revenues can emerge.

SCP0 FAQ

What was Scancell Holdings’s price range in the past 12 months?
Scancell Holdings lowest stock price was €0.72 and its highest was €2.90 in the past 12 months.
What is Scancell Holdings’s market cap?
Scancell Holdings’s market cap is €126.67M.
When is Scancell Holdings’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Scancell Holdings’s earnings last quarter?
Scancell Holdings released its earnings results on Oct 23, 2026. The company reported -€0.14 earnings per share for the quarter.
Is Scancell Holdings overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Scancell Holdings pay dividends?
Scancell Holdings does not currently pay dividends.
What is Scancell Holdings’s EPS estimate?
Scancell Holdings’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Scancell Holdings have?
Scancell Holdings has 121,223,070 shares outstanding.
What happened to Scancell Holdings’s price movement after its last earnings report?
Scancell Holdings reported an EPS of -€0.14 in its last earnings report. Following the earnings report the stock price went up 9.188%.
Which hedge fund is a major shareholder of Scancell Holdings?
Currently, no hedge funds are holding shares in DE:SCP0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology